The updated recommendations, published in the journals Neurology and Headache, prioritize individualized care for patients who experience four or more migraine days per month. Experts emphasize that the range of preventive options has expanded significantly, moving beyond traditional classes to include newer, migraine-specific therapies. These medications—which range from daily oral tablets to monthly or quarterly injections—are designed to minimize symptoms that often include nausea, sensory sensitivity, and severe cognitive impairment.

Clinicians are advised to evaluate the impact of migraine on a patient’s overall quality of life when selecting a treatment plan. Because some preventive agents also address comorbid conditions, such as hypertension or mood disorders, the selection process should involve a discussion of evidence strength, potential side effects, and cost. Author Tamara Pringsheim of the University of Calgary noted that if one treatment fails, the current evidence suggests that shifting to a different class of medication may still provide effective relief. The guideline, endorsed by the American Academy of Family Physicians, advocates for a shared decision-making model to ensure patients find the regimen best suited to their specific neurological needs.